The F.D.A. suspends use of a Glaxo antibody drug in the U.S. as an Omicron subvariant spreads.

Health
By BY ADEEL HASSAN from NYT Health https://ift.tt/cHEVJZ2
via IFTTT Coronavirus (2019-nCoV), Coronavirus Omicron Variant, Drugs (Pharmaceuticals) Manufacturers said lab testing revealed that the authorized dosage of the drug was not sufficiently potent against BA.2.

Comments

Popular posts from this blog

F.D.A. Poised to Restrict Access to Covid Vaccines

U.S. Will No Longer Recommend Covid Shots for Children and Pregnant Women